粘膜黑色素瘤:异质性疾病的治疗策略
Jane Mattei1, Marcio F Chedid2,3,4
1Department of Medical Oncology, The University of Texas at San Antonio, San Antonio (Texas), USA.
Current pharmaceutical design
|January 26, 2026
概括
粘膜黑色素瘤 (MM) 是呼吸道,胃肠道和泌尿器官的罕见癌症,其起源不明. 首选的是手术切除,但淋巴结采样实用性尚不清楚,治疗反应与皮肤黑色素瘤不同.
科学领域:
- 在瘤学瘤学.
- 黑色素瘤研究 黑色素瘤研究
- 癌症病原发生的原因 癌症病原发生的原因
背景情况:
- 粘膜黑色素瘤 (MM) 是一种罕见但具有攻击性的癌症,起源于呼吸道,胃肠道和泌尿器官的非阳光照射的粘膜内.
- 黑色素瘤占所有黑色素瘤诊断的不到2%,没有报告发生率显著增加.
- 粘膜性黑色素瘤的精确病原发生仍然在很大程度上是未知的,这对向治疗构成了挑战.
研究的目的:
- 审查近期治疗粘膜黑色素瘤的进展.
- 讨论目前对MM生物学的理解及其与皮肤黑色素瘤的差异.
- 评估手术干预和新兴治疗方法在管理MM中的作用.
主要方法:
- 这篇编辑综合了有关粘膜膜黑色素瘤治疗的当前文献和临床观察.
- 它分析了手术切除和淋巴结管理策略的疗效.
- 它讨论了免疫检查点抑制剂在MM中的应用和结果.
主要成果:
- 完全的外科切除是区域性粘膜黑色素瘤的首要治疗方法.
- 在MM中,常规淋巴结采样和剖析的临床意义尚未最终确定.
- 虽然免疫检查点抑制剂显示出希望,但由于明显的生物学差异,它们在MM中的有效性通常比皮肤黑色素瘤少.
结论:
- 粘膜黑色素瘤具有独特的生物特征,需要量身定制的治疗方法.
- 进一步的研究至关重要,以澄清淋巴结分期的作用,并优化MM的全身疗法.
- 了解MM生物学的进步为改善治疗策略和患者治疗结果铺平了道路.
相关概念视频
Treatment Strategies for Psychological Disorders
756
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
756
Parkinson's Disease: Treatment
1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment
854
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
854
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.2K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.2K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.5K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.5K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


